Rabiya Tuma
Oncology and HCP Editorial Lead at HealthCentral Corporation
Oncology and HCP Editorial Lead at Oncology News Central
Oncology and HCP Editorial Lead at Patient Power
Oncology and HCP editorial lead @RemHealthMedia, @OBRtweets and @PatientPower. Science and medical writer, former bench scientist. Tweets are my own. She/her
Articles
-
Mar 28, 2025 |
oncologynewscentral.com | Youssef Rddad |Rabiya Tuma |Leah Lawrence
On March 21, the U.S. Food and Drug Administration (FDA) sent a letter from its Office of Prescription Drug Promotion to Taiho Oncology, claiming that data posted on the company’s healthcare provider branded website contained “false or misleading” claims about the benefits of futibatinib (Lytgobi) tablets used to treat certain bile duct cancers.
-
May 7, 2024 |
oncologynewscentral.com | Leah Lawrence |Youssef Rddad |Rabiya Tuma |Ursula Matulonis
-
Apr 18, 2024 |
obroncology.com | Rabiya Tuma
On April 18, the U.S. Food and Drug Administration approved alectinib (Alecensa) for the treatment of adults with early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. The approval is based on results from the ALINA trial, which compared single-agent alectinib with platinum-based chemotherapy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 371
- Tweets
- 381
- DMs Open
- Yes
RT @LungCancerRx: BIG NEWS at #ASCO25: @LungCancerRx is launching its first-ever podcast! Join us for a LIVE recording with @jillfeldman4…
RT @OncBrothers: #WCLC24 ~5 wks away! Current SoC + how is the data from #WCLC24 @IASLC impact our clinical practice at Advancements in Onc…
RT @OncNewsCentral: "Medicine, and within that oncology, is an amazing career. But it can be totally encompassing at times. At the end of t…
